|

ACE-232 tablets Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Acerand Therapeutics (Hong Kong) Limited1

Indications

  • mCRPC (Metastatic Castration-resistant Prostate Cancer)1
  • Prostate Cancer (Adenocarcinoma)1
  • Cancer1

La Jolla, California1 trial

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

University of California San Diego, Moores Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.